Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GCC2005 in Relapsed or Refractory NK and T-cell Malignancies
NCT06699771Phase 1Recruiting
- Sponsor
- GC Cell
- Start
- Mar 2025
- Primary completion
- Aug 2027
- Modality
- CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GCC2005 in T-cell lymphoma and natural killer cell lymphoma (NKCL), sponsored by GC Cell. Primary endpoints: Adverse Events at 18 months, Maximum Tolerated Dose at 18 months and 3 more. Started Mar 2025; status: recruiting.
02
Drugs
GCC2005
03
Conditions
T-cell lymphomanatural killer cell lymphoma (NKCL)
Beyond the preview
Go deeper on NCT06699771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06699771.